Inicio › Cáncer de seno › Minnesota

Ensayos clínicos de Cáncer de seno en Minnesota

64 estudios sobre Cáncer de seno buscan participantes en Minnesota.

Ciudades en Minnesota

Texto oficial del estudio (inglés)

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Mayo Clinic - Rochester, Rochester

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT05696626

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Mercy Hospital, Coon Rapids
Minnesota Oncology Hematology PA-Maplewood, Maplewood
Abbott-Northwestern Hospital, Minneapolis
y 6 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT03418961

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Research Facility, Rochester

ReclutandoFase 1/2

Todas las edades · Todos los sexos · Actualizado el 12 nov 2026 · NCT06590857

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Mayo Clinic Cancer Center, Rochester
HealthPartners Frauenshuh Cancer Center, Saint Louis Park

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT07007559

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

Metro-Minnesota Community Oncology Research Consortium, Saint Paul

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT03424005

The Vanguard Study: Testing a New Way to Screen for Cancer

Minneapolis VA Medical Center, Minneapolis

ReclutandoSe aceptan voluntarios sanos

Edades de 45 a 75 · Todos los sexos · Actualizado el 6 nov 2026 · NCT06995898

Collecting Patient-Reported Experiences With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy

Mayo Clinic in Rochester, Rochester

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT06953245

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Mayo Clinic, Rochester

Reclutando

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07214532

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Mayo Clinic, Rochester

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT05315700

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Minnesota Oncology Hematology, P.A., Minneapolis

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT06982521

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
Mayo Clinic in Rochester, Minnesota, Rochester
Metro-Minnesota Community Clinical Oncology, Saint Louis Park

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07174336

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

University of Minnesota Medical Center, Minneapolis

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06790693

E-Mindfulness Approaches for Living After Breast Cancer

Essentia Health Saint Joseph's Medical Center, Brainerd
Essentia Health Cancer Center, Duluth
Mayo Clinic Health Systems-Mankato, Mankato
y 1 más

ReclutandoFase 3

Edades de 18 a 50 · Todos los sexos · Actualizado el 4 nov 2026 · NCT06748222

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Mayo Clinic in Rochester, Minnesota, Rochester

ReclutandoFase 2

Edades de 18 en adelante · Mujeres · Actualizado el 4 nov 2026 · NCT07287098

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Riverwood Healthcare Center, Aitkin
Mayo Clinic Health System in Albert Lea, Albert Lea
Essentia Health - Baxter Clinic, Baxter
y 49 más

ReclutandoEstudio observacionalSe aceptan voluntarios sanos

Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

USOR Minnesota Oncology Hematology, Maplewood

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT05579366

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Mayo Clinic Health System in Albert Lea, Albert Lea
Essentia Health Saint Joseph's Medical Center, Brainerd
Minnesota Oncology - Burnsville, Burnsville
y 33 más

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06418204

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Mayo Clinic - Rochester, Rochester

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07213791

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Riverwood Healthcare Center, Aitkin
Essentia Health - Baxter Clinic, Baxter
Sanford Joe Lueken Cancer Center, Bemidji
y 48 más

ReclutandoFase 3

Edades de 18 a 60 · Mujeres · Actualizado el 4 nov 2026 · NCT05879926

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Avera Cancer Institute - Marshall, Marshall

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07405801

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Healthpartners Regions Specialty Clinics, Saint Louis Park
Healthpartners Regions Specialty Clinics, Saint Paul

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT07173751

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Mayo Rochester, Rochester

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 oct 2026 · NCT07109726

Avera Cancer Sequencing and Analytics Protocol (ASAP)

Avera Cancer Institute - Marshall, Marshall

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 oct 2026 · NCT05142033

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Metro Minnesota Community Oncology Consortium (MMCORC), Saint Louis Park

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT06401421

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Health Partners Frauenshuh Cancer Center, Saint Louis Park
Health Partners Cancer Center at Regions Hospital, Saint Paul

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT06172478

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Minnesota Oncology-Sarah Cannon Research Institute, Maple Grove

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT07287917

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Minnesota Oncology Hematology, P.A., Burnsville
Minnesota Oncology Hematology, P.A., Coon Rapids
Minnesota Oncology Hematology, P.A., Edina
y 5 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 19 oct 2026 · NCT07062965

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Mayo Clinic, Rochester

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT06374459

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

Mayo Clinic Rochester, Rochester

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 oct 2026 · NCT07311993

Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities

Mayo Clinic in Rochester, Rochester

Reclutando

Edades de 18 en adelante · Mujeres · Actualizado el 5 oct 2026 · NCT06058650

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

University of Minnesota, Masonic Cancer Center, Minneapolis
Mayo Clinic, Rochester

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06369285

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

Mayo Clinic in Rochester, Rochester

ReclutandoFase 2Se aceptan voluntarios sanos

Edades de 18 a 45 · Mujeres · Actualizado el 1 oct 2026 · NCT05557877

PRE-ISPY Phase I/II Oncology Platform Program

University of Minnesota Masonic Cancer Center, Minneapolis
Mayo Clinic Comprehensive Cancer Center, Rochester

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT05868226

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Mayo Clinic, Rochester

Reclutando

Edades de 30 en adelante · Mujeres · Actualizado el 25 sept 2026 · NCT02945579

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Research Site, Saint Paul

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06103864

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site, Minneapolis

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07085767

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Mayo Clinic, Rochester

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT07340541

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

University of Minnesota Masonic Cancer Center, Minneapolis

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT07216105

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Rochester

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT06072612

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Mayo Clinic, Rochester

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT06488378

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.